Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review

Página do item simplificado
dc.contributor.authorScarim, Caue Benito [UNESP]
dc.contributor.authorRibeiro, Aline Rimoldi
dc.contributor.authorRosa, Joao Aristeu da [UNESP]
dc.contributor.authorChin, Chung Man [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.date.accessioned2018-11-26T17:51:39Z
dc.date.available2018-11-26T17:51:39Z
dc.date.issued2018-03-01
dc.description.abstractChagas disease is a protozoan infection that was identified over a century ago. No drugs are available to treat the indeterminate and determinate chronic phases of the disease. Success of a drug design is dependent on correct biological evaluation. Concerning new drug designs for Chagas disease, it is essential to first identify the most effective, existing, experimental chronic protocols that can be used for comparison purposes. Here, we present a literature review regarding experimental models with chronic Chagas disease to evaluate the efficacy of benznidazole (BZN). We searched literature published in PubMed and Web of Science databases, using these keywords: animal model, BZN, Chagas disease, T. cruzi, and chronic phase, with no timeframe limitations. We excluded articles involving acute phase animal models and/or those without BZN treatment. The selected studies were conducted using different BZN concentrations (10mg-100mg) involving several different periods (5-70 days). Concentrations and durations of use are directly related to side effects, but do not prevent chronic tissue lesions. BZN use during the late/chronic phases of Chagas disease is unable to eliminate amastigote forms present in infected tissues. This study suggests the administration of a lower BZN concentration (<100mg/kg/day) during the chronic phase of the animal model, as this had been reported to result in fewer side effects.en
dc.description.affiliationUniv Estadual Paulista, Dept Farmacos & Medicamentos, Fac Ciencias Farmaceut, Araraquara, SP, Brazil
dc.description.affiliationUniv Estadual Campinas, Inst Biol, Dept Parasitol, Campinas, SP, Brazil
dc.description.affiliationUniv Estadual Paulista, Dept Ciencias Biol, Fac Ciencias Farmaceut, Araraquara, SP, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Dept Farmacos & Medicamentos, Fac Ciencias Farmaceut, Araraquara, SP, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Dept Ciencias Biol, Fac Ciencias Farmaceut, Araraquara, SP, Brazil
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.format.extent133-140
dc.identifierhttp://dx.doi.org/10.1590/0037-8682-0337-2017
dc.identifier.citationRevista Da Sociedade Brasileira De Medicina Tropical. Brasilia: Soc Brasileira Medicina Tropical, v. 51, n. 2, p. 133-140, 2018.
dc.identifier.doi10.1590/0037-8682-0337-2017
dc.identifier.fileS0037-86822018000200133.pdf
dc.identifier.issn0037-8682
dc.identifier.lattes9734333607975413
dc.identifier.orcid0000-0003-4141-0455
dc.identifier.scieloS0037-86822018000200133
dc.identifier.urihttp://hdl.handle.net/11449/164200
dc.identifier.wosWOS:000432390600003
dc.language.isoeng
dc.publisherSoc Brasileira Medicina Tropical
dc.relation.ispartofRevista Da Sociedade Brasileira De Medicina Tropical
dc.relation.ispartofsjr0,658
dc.rights.accessRightsAcesso aberto
dc.sourceWeb of Science
dc.subjectBenznidazole
dc.subjectChagas disease
dc.subjectChronic phase
dc.titleResponse to different benznidazole doses in animal models of chronic phase Chagas disease: a critical reviewen
dc.typeResenha
dcterms.rightsHolderSoc Brasileira Medicina Tropical
unesp.author.lattes9734333607975413[4]
unesp.author.orcid0000-0003-4141-0455[4]

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S0037-86822018000200133.pdf
Tamanho:
976.22 KB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Artigos - Fármacos e Medicamentos - FCFAR
Artigos - Ciências Biológicas - FCFAR